Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Drug-resistance mechanism in melanoma
Clinical trials in melanoma patients carrying
B-RAF
gene mutations have shown promising results with the B-RAF kinase inhibitor PLX4032, but many patients go on to become resistant. Two papers now uncover possible mechanisms for this resistance. Nazarian
et al
. report that melanomas can acquire...
Alternative Titles
Full title
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3143360
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3143360
Other Identifiers
ISSN
0028-0836
E-ISSN
1476-4687
DOI
10.1038/nature09626
